Adjuvant Sequential Chemotherapy for Salivary Duct Carcinomas: A Retrospective Comparative Analysis
Current cisplatin-based adjuvant chemotherapy did not significantly improve treatment outcomes of SDC patients over the surgery and adjuvant radiation. Further development or clinical studies are required to improve the outcomes of SDC, including chemotherapeutic, biomarkers, immune checkpoint inhibitors, or treatment strategies.
Authors
- Man Ki Chung (ORCID: https://orcid.org/0000-0002-1435-7786)
- Nayeon Choi (ORCID: https://orcid.org/0000-0002-0962-0594)
- Hyun Ae Jung (ORCID: https://orcid.org/0000-0002-1583-4142)
- Myung‐Ju Ahn (ORCID: https://orcid.org/0000-0002-5740-9654)
- Se‐Hoon Lee (ORCID: https://orcid.org/0000-0002-9219-3350)
- Younghac Kim (ORCID: https://orcid.org/0000-0002-3276-1408)
- Dongryul Oh (ORCID: https://orcid.org/0000-0002-5643-5519)
- Young‐Ik Son (ORCID: https://orcid.org/0000-0002-2114-8085)
- Yong Chan Ahn (ORCID: https://orcid.org/0000-0002-1971-8472)
- Eun‐Hye Kim (ORCID: https://orcid.org/0000-0002-7210-6272)
- Jin Yong Kim (ORCID: https://orcid.org/0000-0002-4306-1597)
- Sehhoon Park
Institutions
- Samsung Medical Center (KR)
- Sungkyunkwan University (KR)
Publication Details
- Journal
- Oncology
- Published
- 2024-12-23
- DOI
- https://doi.org/10.1159/000543281
- Primary Topic
- Salivary Gland Tumors Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00